Brokerages Anticipate Sanofi (NYSE:SNY) Will Announce Quarterly Sales of $9.98 Billion
Analysts expect that Sanofi (NYSE:SNY) will post $9.98 billion in sales for the current quarter, according to Zacks. Two analysts have provided estimates for Sanofi’s earnings, with the highest sales estimate coming in at $10.23 billion and the lowest estimate coming in at $9.73 billion. Sanofi posted sales of $9.20 billion during the same quarter last year, which would indicate a positive year over year growth rate of 8.5%. The business is scheduled to report its next quarterly earnings report before the market opens on Monday, July 31st.
According to Zacks, analysts expect that Sanofi will report full year sales of $9.98 billion for the current year, with estimates ranging from $40.32 billion to $42.03 billion. For the next financial year, analysts forecast that the business will report sales of $42.39 billion per share, with estimates ranging from $42.21 billion to $42.57 billion. Zacks’ sales calculations are an average based on a survey of research firms that cover Sanofi.
Sanofi (NYSE:SNY) last announced its earnings results on Friday, April 28th. The company reported $0.76 earnings per share for the quarter, topping analysts’ consensus estimates of $0.73 by $0.03. Sanofi had a net margin of 26.55% and a return on equity of 25.89%. The business had revenue of $8.65 billion during the quarter, compared to the consensus estimate of $8.40 billion. The company’s quarterly revenue was up 1.2% compared to the same quarter last year.
A number of equities research analysts recently commented on the stock. BidaskClub lowered shares of Sanofi from a “buy” rating to a “hold” rating in a report on Wednesday, July 5th. Berenberg Bank lowered shares of Sanofi from a “buy” rating to a “hold” rating in a report on Thursday, May 11th. Argus assumed coverage on shares of Sanofi in a report on Thursday, April 6th. They set a “buy” rating and a $50.00 price target for the company. J P Morgan Chase & Co reiterated a “neutral” rating on shares of Sanofi in a report on Thursday, April 20th. Finally, TheStreet upgraded shares of Sanofi from a “c+” rating to a “b-” rating in a report on Monday, April 24th. Two analysts have rated the stock with a sell rating, eight have issued a hold rating and five have assigned a buy rating to the stock. The stock has an average rating of “Hold” and a consensus price target of $67.67.
A number of hedge funds and other institutional investors have recently modified their holdings of SNY. Huntington National Bank raised its position in shares of Sanofi by 11.4% in the second quarter. Huntington National Bank now owns 4,963 shares of the company’s stock valued at $238,000 after buying an additional 508 shares during the period. BB&T Corp raised its position in shares of Sanofi by 2.1% in the second quarter. BB&T Corp now owns 168,978 shares of the company’s stock valued at $8,096,000 after buying an additional 3,514 shares during the period. Gradient Investments LLC raised its position in shares of Sanofi by 157.3% in the second quarter. Gradient Investments LLC now owns 16,428 shares of the company’s stock valued at $787,000 after buying an additional 10,044 shares during the period. Rehmann Capital Advisory Group raised its position in shares of Sanofi by 0.7% in the second quarter. Rehmann Capital Advisory Group now owns 7,235 shares of the company’s stock valued at $347,000 after buying an additional 47 shares during the period. Finally, Aperio Group LLC raised its position in shares of Sanofi by 17.8% in the second quarter. Aperio Group LLC now owns 681,230 shares of the company’s stock valued at $32,638,000 after buying an additional 102,804 shares during the period. Institutional investors and hedge funds own 9.84% of the company’s stock.
Shares of Sanofi (NYSE SNY) traded down 0.73% during trading on Friday, reaching $47.71. 941,576 shares of the company were exchanged. The stock has a market capitalization of $120.49 billion, a PE ratio of 11.50 and a beta of 0.89. The stock has a 50-day moving average price of $48.37 and a 200-day moving average price of $45.39. Sanofi has a one year low of $36.81 and a one year high of $50.24.
TRADEMARK VIOLATION WARNING: This story was published by American Banking News and is owned by of American Banking News. If you are reading this story on another domain, it was illegally copied and republished in violation of United States & international trademark and copyright legislation. The correct version of this story can be accessed at https://www.americanbankingnews.com/2017/07/23/brokerages-anticipate-sanofi-nysesny-will-announce-quarterly-sales-of-9-98-billion.html.
Sanofi Company Profile
Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. The Company’s segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company’s pharmaceuticals operations.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.